Cyclacel Pharmaceuticals, Inc.
9:30 AM - 9:45 AM (EST), Monday, February 6, 2023 ・ Music Box
As a clinical-stage, biopharmaceutical company, Cyclacel develops innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates to address oncology and hematology indications.
Ticker:
CYCC; CYCCP
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
1997
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Fadraciclib
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
